Skip to main content
Fig. 7 | BMC Medicine

Fig. 7

From: Combination of an autophagy inhibitor with immunoadjuvants and an anti-PD-L1 antibody in multifunctional nanoparticles for enhanced breast cancer immunotherapy

Fig. 7

Autophagy inhibition in the tumor enhances the anticancer activity of MNPs. a LC3B-positive puncta, as detected by immunofluorescence assay with an anti-LC3B antibody, followed by confocal microscopy. Cell nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI; blue). Scale bar, 20 μm. b Number of LC3B-positive puncta per cell quantified from ~20 cells treated with different formulations. c Representative Western blots for SQSTM1 and LC3B-II. d Relative protein levels of LC3B-II and SQSTM1, normalized to levels of GAPDH. Data are shown as mean ± SD (n = 3). One-way ANOVA was performed. *P < 0.05, **P < 0.01. Mice injected with 5% glucose solution were set as the control group. CpG, immunopotentiator; CQ, chloroquine; N, nanoparticles; N/A, nanoparticles coated with atezolizumab; OVA, ovalbumin; PTX, paclitaxel; S, solution

Back to article page